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Summary 
The monoclonal antibody OX22 defines a functional split within CD4 + T cells in the rat, with 
OX22his h cells  mainly producing  interleukin  2  (IL-2)  and  interferon 3~ and  responsible  for 
delayed-type hypersensitivity responses,  and OX22 j~  cells mainly producing IL-4 and -5 and 
responsible for providing B cell help.  There are reciprocal interactions between OX22his h and 
OX22 I~  cells, and it has been suggested that the OX22 l~  subset has a role in the prevention 
of autoimmunity. We have used OX22 in vivo to define the role of these subsets  in mercuric 
chloride-induced autoimmunity in the Brown Norway rat.  In this model, there is polyclonal 
B cell activation and animals develop widespread tissue injury. Treatment of thymectomized animals 
with OX22 led to a profound reduction in the number of OX22his h T  ceils in the peripheral 
blood. OX22-treated animals consistently developed more severe tissue injury than controls given 
an irrelevant antibody of the same isotype. Control animals pretreated with broad spectrum 
antimicrobial drugs showed milder tissue injury, but this protective effect of antimicrobials was 
lost in OX22-treated animals. Transfer of naive T cells to OX22-treated animals provided protection, 
but if T cells were depleted in vitro of OX22 high cells before transfer, this effect was lost. These 
data provide evidence for a protective immunoregulatory role for OX22 high T cells in mercuric 
chloride-induced autoimmunity. 
T 
he functional split of T cells defined by the cell-surface 
markers CD4 and CD8 is well-known, with helper/in- 
ducer  T  cells  defined  by  expression  of  CD4  and  sup- 
pressor/cytotoxic T  cells defined by CDS.  There has been 
considerable recent progress in the characterization of func- 
tionally distinct T  cell subpopulations within these major 
categories.  In the mouse, CD4 + cells can usually be sub- 
divided on the basis of the cytokines they secrete, with one 
subset (Thl) predominantly producing IL-2 and fiN-3', and 
a second subset (Th2) predominantly producing IL-4 and IL-5 
and responsible for providing B cell help (1). There is evi- 
dence of a similar functional split  within CD4 ~ T  cells in 
the rat (2, 3) and in humans (4).  A number of phenotypic 
markers have been used to define subsets of CD4 § T  cells, 
and one of the best studied of these is the CD45 molecule, 
also known as the leukocyte common antigen (5-7). CD45 
occurs in several different isoforms that are derived by differen- 
tial splicing of at least three variable exons situated near the 
5' end of the gene (8). A number of mAbs are available that 
recognize specific  CD45 isoforms denoted CD45RO, CD45RA, 
CD45RB,  and CD45RC  (9).  In the rat,  the mAb MRC- 
OX22 binds to a high molecular weight isoform (CD45RB 
and/or CD45RC)  and defines subpopulations of CD4 + T 
cells with different functions (2,  10). OX22 hish CD4 § cells 
produce IL-2 and IFN-% but little IL-4, whereas OX22 l~ 
CD4 + cells provide B cell help, producing more IL-4 with 
less IL-2 and IFN-3~ (2,  10). Transfer of OX22his h CD4. § T 
cells into nude athymic rats has been reported to induce a 
severe wasting disease  with  inflammation in a number of 
organs, whereas transfer of OX22 l~  CD4 § T  cells has no 
such effect (11). Furthermore,  if unfractionated CD4 §  T 
cells were transferred, i.e., containing a mixture of approxi- 
mately two-thirds  OX22hi8  h and  one-third  OX22 I~  the 
nude recipients remained well, indicating that there is an in- 
teraction between the two subsets, with the OX22 l~  popu- 
lation apparently able to inhibit the deleterious effect of the 
0X22 high cells  (11). 
Mercuric chloride (HgCI2)  is a  T  cell-dependent poly- 
clonal B cell activator that induces autoimmunity in suscep- 
tible rodent strains. In the Brown Norway (BN) 1 rat, HgC12 
induces a self-limiting autoimmune syndrome with autoreac- 
rive CD4 + T cells (12,  13), hypergammaglobulinemia pre- 
dominantly affecting the IgE class (14), and a number of IgG 
autoantibodies including antibodies to glomerular basement 
membrane (GBM) (15). We have recently reported (16) that 
HgClz-treated BN rats develop widespread tissue injury, par- 
I Abbreviations used in tkis  paper: BN, Brown Norway; GBM, glomerular 
basement  membrane. 
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tures  resembling  GVHD.  We have examined the effect of 
OX-22 treatment in vivo on the autoimmune response in- 
duced in BN rats by HgC12.  Our  results provide evidence 
for a protective regulatory role of OX22 high T  cells in this 
experimental  model. 
Materials and Methods 
Experimental Model.  BN rats were obtained from OLAC (Bi- 
cester, UK) and a breeding colony established.  For all experiments, 
animals were used in age- and sex-matched groups. Rats were given 
HgC12 diluted in distilled  water by five subcutaneous injections 
over a 7-d period, each injection consisting of 1 mg/kg HgCI2. 
Animals were weighed regularly and serial blood samples were taken 
from a tail vein for analysis of lymphocyte subsets (heparinized blood) 
and for separation of serum for assay of anti-GBM antibodies. Where 
antimicrobial pretreatment was used,  animals  were given tylosin 
(Tylan|  Eli Lilly Italia,  Florence,  Italy) 10 m~/kg per day sub- 
cutaneously  for  5  d,  metronidazole  (Torgyl|  May  &  Baker, 
Dagenham, UK) 20 mg/kg per day subcutaneously for 5 d, and 
ivermectin (Ivomec|  Merck, Sharp & Dohme, Hoddesdon, Herts, 
UK) 200 #g/kg subcutaneously on the first and fifth days. For the 
in vivo mAb treatment, animals were given mAbs by daily intrave- 
nous injection for 5 d immediately before starting HgC12. 
Anti-GBM Antibody Assay.  Sera were assayed for anti-GBM an- 
tibody by a solid phase RIA was as described previously (17). Briefly, 
a collagenase digest of normal rat glomeruli was coated onto mi- 
crotiter plates (Dynatech Laboratories,  Inc., Chantilly, VA). After 
washing, the plates were incubated with test or control sera and 
bound  antibody  detected  with  goat  anti-rat  IgG  (Sigma  Im- 
munochemicals, Poole, Dorset, UK) radiolabeled  with 22sI by the 
chloramine T method. Sera were assayed in triplicate and the mean 
result expressed as a percentage of a strongly positive reference serum. 
In Vivo mAb Treatment.  Thymectomies were performed at age 
3-4 wk by suction via a partial sternotomy wound under ether 
anesthesia.  Animals were allowed to recover for at least 2 wk and 
then'given mAbs 200 #g daily for five consecutive days by intrave- 
nous injection via a tail vein. The mAbs were produced in tissue 
culture or ascites, purified on protein A or by ion-exchange chro- 
matography, then dialyzed into PBS and filter sterilized. Test animals 
received MKC OX22 or MRC OX8, and control animals received 
an isotype-matched (IgG1)  mouse myeloma protein with an un- 
determined specificity, derived from a mineral oil-induced plasmacy- 
toma (MOPC 21; Sigma). 
Flow Cytometry.  Blood was taken from the tail into heparinized 
tubes and PBL preparations made by density centtifugation on Ficoll- 
Hypaque (Pharmacia,  Milton Keynes, UK). All dilutions were in 
PBS containing 1% BSA (British Drug House, Poole, Dorset, UK), 
and all incubation stages were at 4~  for 45 rain. Cells were plated 
at 5  x  105 cells per well in a microtiter plate and stained  with 
MRC  OX22  (10  #g/ml)  followed by  FITC-conjugated  sheep 
anti-mouse Ig that had been adsorbed with rat serum proteins 
(Sigma),  diluted 1 in 250.  Double-staining analysis was also per- 
formed on PBLs,  using biotinylated OX52 (pan-T cell) (18) (10 
#g/ml) as the second antibody and streptavidin-PE (Serotec Ltd., 
Oxford, Oxon,  UK) (diluted 1 in 250)  as the second detection 
reagent. For analysis of the cells used in the cell transfers, first anti- 
bodies were OX22  and OX52,  and detection was  with  FITC- 
conjugated sheep anti-mouse Ig. Cells were analyzed using a flow 
cytometer (Epics Profile; Coulter, Luton, UK). Appropriate controls 
were incorporated to assess autofluorescence and nonspecific staining. 
Cell Transfers.  Cell transfers were administered on day 10 after 
starting HgC12. Nine syngeneic naive BN rats were used as spleen 
cell  donors.  Spleens  were removed into  tissue  culture medium 
(IMDM; Gibco, Paisley, Scotland), red cells lysed with Tris-buffered 
ammonium chloride, and single cell suspensions prepared by sieving. 
Nylon wool columns were used to prepare purified T cells, which 
were then pooled and counted. One portion of these was kept for 
cell transfers,  and one portion was subjected  to depletion in vitro 
of OX22  ~h T  cells. To achieve this,  T  cells were incubated in a 
96-well  plate at 4  x  105 cells/well  with 50 t~g OX22,  washed 
twice, and then incubated with magnetic beads coated with sheep 
anti-mouse IgG (Dynal AS, Oslo, Norway), using a 10:1 bead/ 
target ratio. A magnet was used to extract cells bound to the beads. 
Remaining cells were washed, resuspended in tissue culture medium, 
and infused intravenously into HgC12-treated  animals  (4  x  107 
cells per animal).  Aliquots were kept at each stage for analysis by 
flow cytometry. 
Histological Methods.  Animals from each group were killed at 
various  stages  of the experiment and immediate necropsies  per- 
formed. Organs were fixed in buffered formalin, routinely processed, 
and embedded in paraffin wax. 3--4/~m sections  were evaluated 
for histological alterations with haematoxylin-eosin stain. All sec- 
tions were examined by an experienced histopathologist (S. Thiru) 
without knowledge of the experimental groups. Severity of inflam- 
matory changes in the gut, liver, and lung was graded for each 
animal according to an arbitrary scale: 0, normal; 1, mild; 2, mild 
to moderate; 3, moderate to severe; and 4, severe. These mores were 
then added up to give a total tissue injury score for each animal, 
with a possible  maximum score of 12. 
StatisticalAnalysis.  Serial data on anti-GBM antibody titers and 
body weight were analyzed by repeated measures analysis of vari- 
ance using a computer program (PC+; SPSS Inc., Chicago, IL). 
Histological data were analyzed by the permutation test for two 
independent samples (19). 
Results 
Experimental Design.  The results are reported of four ex- 
periments involving a total of 96 animals (summarized in Fig. 
1). In the first experiment (n  =  15), five rats received OX22, 
five received OX8 to deplete CD8 + T  cells (20), and five re- 
ceived no mAb.  In the second experiment (n  =  27),  nine 
rats received OX22,  nine received OX8,  and nine received 
A5,  an irrelevant mAb of the same isotype (21). These ex- 
periments were designed to analyze the effect of these mAbs 
on the immunoregulation of the autoantibody response (20), 
and so detailed histological analysis was not carried out on 
all animals. However, the external appearances of the animals 
were scored according to an arbitrary scale to assess the severity 
of the mucocutaneous inflammation,  and in experiment 2, 
histology was  obtained from nine of the animals  (three in 
each group). Taking experiments I and 2 together, there was 
a significant difference between the groups in terms of ex- 
ternal scores (p  =  0.04, Kruskal-Wallis analysis of variance), 
with the OX22 group having more severe inflammation and 
the OX8 group not being significantly different from con- 
trois. The histological analysis of nine animals in experiment 
2  showed  that  the OX22-treated  animals  had  more severe 
tissue injury than the controls (p <  0.05) and the OX8 group 
(p  <  0.05).  The  controls  and  the  OX8  group  were  not 
significantly different. 
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Figure 2.  Flow cytometry  analysis. (A) PBLs from untreated  animal, stained with OX22 (LFL1). (B) PBLs from OX22-treated  animal, stained 
with OX22 (LFLI). (C) Nylon wool-separated T cells, stained with OX22 (LFLI). (D) T cells after in vitro depletion of OX22hig  h cells, stained with 
ox22 (LFL  0. 
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injury, we designed the third  and fourth experiments to  8 
confirm and extend this observation. In the third experiment 
(n  =  18), nine animals were pretreated with antimicrobials 
and nine were not. In each group of nine, five received OX22  6 
and four received control mAb.  In the fourth experiment 
(n  =  36), 30 animals were pretreated with antimicrobials 
and six were not. In the pretreated group, six received con- 
trol mAb and 24 received OX22. The OX22-treated animals  o  o  4 
were further subdivided into three groups of eight for the  r 
cell transfers:  eight received unftactionated T cells, eight re- 
ceived OX22-depleted T  cells,  and eight recei~,ed no cell 
transfer.  2 
Flow Cytometry Analysis.  PBLs from untreated animals 
gave a typical profile of staining with OX22, with two peaks 
of positive-staining cells, designated OX22hig  h and OX22  l~  0 
typically accounting for 55-65 % and 30-40% of total PBLs, 
respectively (Fig.  2 A). Using double staining, there was a 
population  of  OX22 high  T  cells  which  accounted  for 
35-45% of total PBLs (data not shown). Animals receiving  Figure 3. 
control mAb showed no difference from untreated animals. 
OX22-treated  animals  showed loss  of the OX22hig  h peak 
(Fig.  2 B) and reduction of the double-staining OX22hig  h T 
cells to 10%  or less of the total.  Flow cytometric analysis 
of the spleen cells used in the cell transfers showed that 96-97% 
of the nylon wool-separated cells were OX52 positive,  i.e., 
a relatively pure population of T cells. This cell preparation 
contained OX22 hiSh and OX22 t~  cells (Fig.  2 C), and after 
in vitro depletion with OX22, the OX22~g  h population had 
been removed (Fig.  2 D). 
Tissue Injury: External Appearances.  As we have reported 
previously (16), rats developed severe inflammation of mu- 
cocutaneous junctions by 10-12 d after HgCh.  In the two 
initial experiments in which various anti-T cell mAbs were 
used, it was a consistent observation that the external inflam- 
mation was most marked in animals that had received OX22. 
As also reported previously (16), antimicrobial pretreatment 
greatly reduced the severity of the mucocutaneous inflam- 
mation, but this was less apparent in the OX22-treated animals, 
in which the protective effect of antimicrobials was overcome 
by the exacerbating effect of OX22  treatment. 
Tissue Injury: Body  Weight.  In  the fourth experiment,  s 
animals were weighed sequentially. Animals not pretreated 
with antimicrobials showed significant weight loss compared  ,~  6 
with pretreated animals (p  =  0.002),  with a mean weight  b  O 
loss of 5.9%  of baseline body weight in the nonpretreated  ~o  4 
group compared with a mean weight gain of 2.4% of base- 
line in the pretreated animals.  There was a trend to greater 
weight loss in the OX22-treated animals than in the con-  2 
trols,  but  this  did  not  quite  reach  statistical  significance 
(p  =  0.06).  o 
Tissue Injury: Histology.  In the third and fourth experi- 
ments, the differences between the tissue injury seen in the 
various groups were quantified using the histological scoring 
system. In the third experiment, OX22-treated animals had 
more severe tissue injury than controls (p <0.0005,  Fig.  3). 
There was no significant protective effect of antimicrobial 
pretreatment in this experiment (data not shown). Fig. 4 shows 
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Experiment 3: effect of OX22 on tissue injury score. OX22 
compared  with control mAb, p <0.0005). 
the effect of OX22 treatment and antimicrobial treatment 
in experiment 4. OX22-treated animals had more severe tissue 
injury than animals receiving control mAb (Fig. 4, first bar 
compared with  third bar  at  each time point,  p  <0.005). 
Within the groups of animals receiving control mAb, an- 
timicrobial pretreated animals had milder tissue injury than 
animals not pretreated (Fig. 4, first bar compared with second 
bar, iv =  0.039). Animals pretreated with antimicrobials and 
then given OX22 were not significantly different from animals 
not pretreated with antimicrobials (Fig. 4, second bar com- 
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Figure 4.  Experiment 4: tissue injury score. Effect of OX22 (first bar 
compared  with third bar  at  each time point, p  <0.005);  antimicrobial 
pretreatment (first bar compared with second bar, p  =  0.039);  and the 
interaction between OX22 and antimicrobials (second bar compared with 
third bar, p  ~  0.32). 
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ment overcame the protective effect of antimicrobial pretreat- 
ment.  Fig.  5  shows histological data for the cell transfer 
recipients:  animals receiving unfractionated T cells had milder 
tissue injury than animals receiving T cells depleted in vitro 
of OX22 high cells (p  =  0.007). 
Anti-GBM Antibody  Titers.  In none of the experiments 
was there any significant difference  in anti-GBM titer between 
OX22-treated animals and controls (Fig. 6). As reported pre- 
viously (16), antimicrobial pretreatment did not affect anti- 
GBM titer. 
Discussion 
From this series of ext~ents,  we conclude the following: 
treatment of thymectomized rats with OX22 in vivo leads 
to loss of OX22 high T cells. Animals treated with OX22 be- 
fore receiving HgC12 develop more severe tissue injury than 
animals receiving a control mAb, and the protective effect 
of antimicrobial pretreatment in this experimental model is 
overcome by OX22 administration. OX22 treatment does 
not affect anti-GBM autoantibody levels. Transfer of unfrac- 
tionated T cells from naive animals to OX22-treated animals 
reduces the severity of tissue injury, but transfer of T  cells 
depleted of OX22hig  h cells confers less protection. Taken to- 
gether, these data provide evidence for the hypothesis that 
OX22hig  h T  cells play a protective immunoregulatory role 
in mercuric chloride-induced autoimmunity. 
The epitope recognized by OX22 is found on macrophages 
and B cells as well as T cells (10, 22). This widespread distri- 
bution might have been expected to decrease the chances of 
administered OX22  antibody affecting a particular T  cell 
subset.  However, our data dearly demonstrate the loss of 
OX22hig  h staining T  cells. We cannot be sure whether this 
represents depletion of the OX22hig  h T cell subset or simply 
modulation of the OX22 target from the cell surface.  The 
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Figure 5.  Experiment 4: tissue injury score in cell transfer recipients 
(0X22-, transfer of T cells depleted in vitro of OX22 + cells; all T cells 
unfractionated,  p  =  0.007). 
1313  Mathieson  et al. 
75  ￿9  A/22/No  cell  transfer 
￿9 A/22/OX22-  T 
￿9  A/22/T  -~ 
￿9  A/m/No  cell  transfer  /~, 
0  I  I  I  I 
0  5  10  15  20 
Time  (days) 
Figure 6.  Experiment 4: serial anti-GMB antibody levels (mean _+ SE 
of the mean). (A) Antimicrobiai pretreatment;  (22) OX22 treatment in 
vivo; (ra) mouse IgG (control mAb); (02(22-) transfer of T cells depleted 
in vitro of OX22 § cells; (7") transfer of unfractionated  T cells. 
50 
m 
(5 
I  .i 
e-, 
.~  2s 
distinction between these possibilities  is not critical since a 
number of in vitro studies have shown that antibodies directed 
against various CD45 epitopes can have functional effects in 
the absence of cell killing (23-27). Our data show functional 
effects of OX22 in vivo,  irrespective of the precise fate of 
the OX22hig  h T  cell subset.  Since CD8 + T  cells  are also 
OX22hi8  h, treatment with OX22 in vivo would be expected 
to affect these cells, as well as the OX22hig  h subset of CD4 + 
T cells. The data from experiments 1 and 2 indicate that OX8 
treatment in vivo, which effectively depletes CD8 + T  cells 
(20),  does  not  worsen  tissue  injury.  We  have conducted 
numerous experiments in which CD8 + T  cells  were de- 
pleted (20), and we have never observed any exacerbation of 
tissue injury as a result of this treatment. Indeed, in many 
cases, OX8-treated animals seemed to have less severe tissue 
injury (our unpublished observations). Depletion of CD8 + 
T cells by OX22 treatment cannot therefore explain our ob- 
servations, and by implication, the effects of OX22 treatment 
in vivo are likely to be due to depletion of OX22hig  h CD4 + 
T  cells. 
In  the  experiments  alluded  to  earlier  (11),  it  was  the 
OX22hig  h subset of T  cells that led to tissue injury in nude 
rats,  and the OX22 I~  subset which were protective. This 
has led to the suggestion (2)  that OX22 l~  CD4 + T  cells 
play a role in the prevention of autoimmunity in vivo. Our 
data on HgC12-induced autoimmunity indicate that in this 
model  the  roles  of these  subsets  are  reversed,  with  the 
OX22  l~  subset having a deleterious effect and the OX22hig  h 
subset playing a protective role. It has been postulated that 
HgC12-induced autoimmunity reflects preferential activation 
of Th2-type CD4 + T  cells, since there is polyclonal B cell 
activation and hyper-IgE (28). In the mouse, IL-4 (predomi- 
nantly a Th2 product) is a key cytokine in HgC12-induced 
autoimmunity (28, 29).  In the rat, IL-4 is mainly produced 
by the OX22 l~  subset of T cells (2). Since it is known that there  are  reciprocal  interactions  between  OX22  high  and 
OX22  l~  T  cells  (11),  if  HgC12  preferentially  activates 
OX22  l~  (i.e.,  Th2-type) cells,  it is perhaps not surprising 
that depletion of OX22  high (i.e., Thl-type) cells should lead 
to exacerbation of tissue injury in this model. There is evi- 
dence that the respective roles of OX22hig  h and OX22  l~  cells 
in alloimmune reactions are more akin to the roles we postu- 
late  in  HgC12-induced  autoimmunity,  with  the  OX22  hish 
subset  having  a  "suppressor"  role  (30)  and  the  OX22  t~ 
subset  being  effector  cells  (31).  The  protective  effect  of 
OX22  high cells which we observed may be strain  specific. BN 
rats  have  anomalous  T  cell  subsets,  with  a  small  CD8 § 
population  (20),  and a high ratio of OX22  l~  to OX22his  h 
CD4 + T  cells  compared with  other strains. 
Genetic factors play an important part in determining the 
response to HgC12.  In the rat, MHC and background genes 
are both  involved in  determining  the  response  to  HgC12 
(32-34).  The MHC haplotype that confers susceptibility is 
RT-I"  (32).  In resistant  strains  of rat,  HgC12 induces im- 
munosuppression,  such that induction of organ-specific au- 
toimmune diseases, e.g., experimental allergic encephalomy- 
elitis (35) or Heymann nephritis  (36), in rat strains which 
are normally fully susceptible, is prevented by prior treatment 
with HgClz. Susceptibility to HgC12-induced immunosup- 
pression is also under the influence of the MHC, with RT-11 
being the key haplotype (37). A hypothesis which would fit 
in with the importance of the balance between Thl and Th2 
cells is that in susceptible strains,  Th2 cells are preferentially 
activated by HgC12, whereas in resistant strains it is a Thl 
response that  predominates  (28).  There  is evidence in  the 
mouse that the MHC genotype determines whether Thl or 
Th2 cells are activated by HgC12,  with a mainly Thl-type 
response in H-2  a mice and a Th2-type response in H-2  s mice 
(28).  Responsiveness in the mouse to HgC12 is linked to the 
MHC class II A ~ molecule,  and coexpression of the other 
class II molecule (the E molecule) in an A ~ strain decreases 
responsiveness (34). There are also examples in the rat in which 
responses channelled via the two class  II molecules appear 
to have opposing immunoregulatory effects (38, 39). Whether 
this applies to the response to HgC12 in the rat is unknown, 
but clearly there is ample precedent for the differential acti- 
vation of regulatory  subsets by different MHC molecules, 
both between and within  particular  haplotypes. 
The effector mechanisms mediating  tissue injury in this 
model are not well-defined. A direct pathogenic role for au- 
toantibodies seems unlikely since in our experiments autoan- 
tibody titers were not affected by OX22 treatment  or an- 
timicrobials, so that there was a dissociation between severity 
of tissue injury and level of autoantibody. A role for granulo- 
cytes is suggested by the infiltration of tissues by these cells 
and  the  development  of a  leucocytoclastic vasculitis  (16). 
OX22  l~  cells have a particular propensity to recruit cells of 
the granulocyte lineage (40), so this could provide one mech- 
anism for the deleterious role of OX22  low cells. As indicated 
earlier,  depletion of CD8 § T  cells in vivo may be associated 
with a protective effect, indicating that CD8 + T  cells may 
play a role as effectors.  Alternatively,  the tissue injury may 
be directly  mediated  by OX22  I~  T  cells.  Although  it  is 
known that OX22~ h T cells mediate some forms of GVHD 
(10), there is evidence that in so-called "syngeneic" GVHD, 
the key effector cell has an OX22  I~  phenotype (41, 42). The 
tissue injury we observed has some similarities with GVHD 
(16), and since our animals had not received a graft, the model 
may more dosely resemble syngeneic GVHD, which is thought 
to be autoimmune  mediated  (43). 
The protective effect of antimicrobial pretreatment is also 
of interest.  The severity of tissue inflammation  in GVHD 
is influenced by microbial load, both in experimental animals 
(44) and in humans (45), with pathogen-free individuals de- 
veloping much less severe disease.  Furthermore,  in human 
diseases characterized by necrotizing leucocytoclastic vascu- 
litis similar to that seen in our animals,  antibiotics alone may 
have useful therapeutic effects (46), and tissue injury is known 
to be exacerbated by intercurrent  infection (47).  One pos- 
sible mechanism for an effect of infection is illustrated by the 
recent demonstration that infection with a nematode can break 
T cell tolerance, apparently preferentially affecting the IL-4- 
producing (Th2-type) subset (48). In our experience,  the pro- 
tective effect of antimicrobials is somewhat variable.  For in- 
stance, in the experiments described here, the effect was seen 
in the fourth experiment but not in the third. This may simply 
reflect variation in the microbial load of different batches of 
animals.  Antimicrobials would not be expected to have any 
effect if the pathogen  load of the animals  is low. 
HgCl2-induced autoimmunity in the BN rat has features 
in common with a number of human autoimmune diseases 
(summarized in reference 49). At present, the treatment  of 
human autoimmunity usually involves the use of nonspecific 
immunosuppressive drugs. If certain lymphocyte subsets have 
deleterious roles and others are protective, therapy could be 
improved by using reagents such as mAbs to specifically target 
the damaging subset. At present, little is known about the 
role of subsets of CD4 + T  cells in humans,  but this is an 
area where further advances could lead to the design of more 
specific  forms of immunotherapy  for human  disease. 
In summary, we have presented evidence that tissue injury 
in  BN  rats  with  HgC12-induced  autoimmunity  is  exacer- 
bated by in  vivo depletion  of OX22hig h T  cells,  and  that 
restoration of this population by cell transfer provides pro- 
tection.  Thus,  OX22hig h T  cells seem to play an important 
protective immunoregulatory role in this model. This finding 
has implications for the understanding of interactions  between 
Thl- and Th2-type cells in the rat,  and may also have rele- 
vance to human  autoimmunity. 
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